RecruitingNot Applicable

AURORA Study-A Transformative Approach to Support PrEP Medication Persistence

United States105 participantsStarted 2023-11-30

Plain-language summary

This study is designed to test the hypothesis that, compared to oral PrEP, use of CAB-LA in underserved populations in a real-world setting supported by a digital health companion program will be associated with greater medication adherence, persistence, retention-in-care, and improved PROs. Patients in the study will receive current standard care for HIV prevention and be offered enrollment in the digital health companion program. Goal of the study is to evaluate medication adherence and persistence in patients receiving CAB-LA vs oral PrEP and who engage with a digital health companion program.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Initiation of or current user of PrEP with CAB-LA, daily FTC/TDF, or daily FTC/TAF prescribed in accordance with the WVHR standard of care practices (based practices on CDC PrEP 2021 Clinical Practice Guidelines) by a licensed HCP * PrEP dispensed by WVHR pharmacy * Access to a smart phone Exclusion Criteria: * Receiving HIV PrEP care outside of WVHR * Positive HIV diagnosis * Contraindication to oral or injectable PrEP therapy * Receiving oral bridging therapy prior to injectable PrEP therapy

What they're measuring

EFFICACY: Medication Adherence

Timeframe: 12-months

Trial details

NCT IDNCT06072443

SponsorWV Health Right, Inc.

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-30

Contact for this trial

Angie Settle, DNP, APRN

304-414-5930 ASettle@wvhealthright.org

View on ClinicalTrials.gov More HIV Infections trials